Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
342 participants
INTERVENTIONAL
2007-07-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
NCT00846391
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
NCT00972322
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
NCT01640873
Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)
NCT01982630
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
NCT02492763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MK0893 80 mg
MK0893 tablets totaling 80 mg once daily.
MK0893
MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo to Metformin
Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
MK0893 60 mg
MK0893 tablets totaling 60 mg once daily.
MK0893
MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo to Metformin
Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
MK0893 40 mg
MK0893 40 mg tablet once daily.
MK0893
MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo to Metformin
Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
MK0893 20 mg
MK0893 20 mg tablet once daily.
MK0893
MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo to Metformin
Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
Metformin
Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
Metformin
Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo
PLA tablets. 12 week treatment period.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo to Metformin
Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK0893
MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Metformin
Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
Placebo to MK0893
Dose-matched placebo tablets to MK0893; taken orally once daily.
Placebo to Metformin
Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients taking insulin or thiazolidinedione (TZD, a peroxisome proliferator-activated receptor \[PPAR\]-gamma agonist)
* Patients who have a contraindication to metformin
21 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007_526
Identifier Type: -
Identifier Source: secondary_id
0893-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.